Trial Profile
A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- 31 Jan 2021 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 31 Jan 2021 Status changed from recruiting to active, no longer recruiting.
- 08 Oct 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.